Krystal Biotech Announces Initiation Of Pivotal Phase 3 Study Of Beremagene Geperpavec In Patients With Dystrophic Epidermolysis Bullosa

Vodka brand

The randomized, double-blind GEM-3 trial will compare repeat dosing of either B-VEC or placebo in approximately 30 dystrophic epidermolysis bullosa (DEB)…


more on globenewswire.com